Today, CDC’s Director Rochelle P. Walensky, M.D., M.P.H., signed a call memo permitting Novavax monovalent COVID-19 boosters for adults.
This motion offers individuals ages 18 years and older the choice to obtain a Novavax monovalent booster as an alternative of an up to date (bivalent) Pfizer-BioNTech or Moderna booster if they’ve accomplished main collection vaccination however haven’t beforehand acquired a COVID-19 booster—and if they can’t or won’t obtain mRNA vaccines.
Some could also be unable to obtain an mRNA vaccine on account of an allergy to a part of an mRNA COVID-19 vaccine, or on account of a historical past of a extreme allergic response (corresponding to anaphylaxis) after a earlier dose of an mRNA COVID-19 vaccine, or an absence of availability of an mRNA vaccine. People ages 18 and older might also select to obtain a Novavax monovalent booster if they’re unwilling to obtain mRNA vaccines, and would in any other case not obtain a booster dose.
FDA’s authorization of monovalent COVID-19 boosters and CDC’s suggestion to be used, are essential steps ahead in our nation’s complete vaccination program—a program that has helped present elevated safety for all Americans towards COVID-19 illness and loss of life.